In this study, we explored the correlation between serum IGFBP2 levels and the severity of hepatic steatosis measured by the controlled attenuation parameter (CAP) in adult patients with MASLD, aiming to provide new insights for the development of potential strategies for the diagnosis and treatment of MASLD. Here, IGFBP2 is linked to metabolic dysfunction-associated steatotic liver disease.